Changes to UK Statutory Scheme go ahead despite pharma criticism
Drug Discovery World
DECEMBER 6, 2023
It intends to set amended payment percentages for 2024 to 2026 based on an allowed growth rate that has been increased to 2%. The proposed adjustment had been criticised as unworkable and likely to result in low-margin branded medicines being withdrawn from the UK market. in 2024, 24% in 2025 and 26.8%
Let's personalize your content